

# A Hugh Mostafid

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4835111/a-hugh-mostafid-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

3,073  
citations

28  
h-index

54  
g-index

113  
ext. papers

4,509  
ext. citations

4.8  
avg. IF

5.34  
L-index

#	Paper	IF	Citations
92	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. <i>European Urology</i> , <b>2019</b> , 76, 639-657	10.2	531
91	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. <i>European Urology</i> , <b>2018</b> , 73, 111-122	10.2	507
90	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , <b>2021</b> , 79, 62-79	10.2	176
89	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> <b>2017</b> , 72, 801-813	10.2	124
88	Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. <i>European Urology</i> , <b>2010</b> , 57, 607-14	10.2	90
87	Quality improvement in multidisciplinary cancer teams: an investigation of teamwork and clinical decision-making and cross-validation of assessments. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3535-43	3.1	80
86	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. <i>Trials</i> , <b>2018</b> , 19,	2.8	78
85	Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". <i>European Urology Focus</i> , <b>2019</b> , 5, 457-466	5.1	73
84	Planning percutaneous nephrolithotomy using multidetector computed tomography urography, multiplanar reconstruction and three-dimensional reformatting. <i>BJU International</i> , <b>2005</b> , 95, 1280-4	5.6	66
83	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. <i>European Urology Focus</i> , <b>2019</b> , 5, 205-223	5.1	66
82	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , <b>2020</b> , 77, 223-250	10.2	60
81	Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. <i>European Urology</i> , <b>2019</b> , 75, 63-71	10.2	57
80	Guideline of guidelines: asymptomatic microscopic haematuria. <i>BJU International</i> , <b>2018</b> , 121, 176-183	5.6	53
79	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). <i>European Urology</i> , <b>2021</b> ,	10.2	51
78	Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. <i>European Urology</i> , <b>2018</b> , 74, 10-14	10.2	49
77	BCG immunotherapy for bladder cancer--the effects of substrain differences. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 580-8	5.5	49
76	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5818-5831	12.9	43

75	Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?. <i>Journal of Urology</i> , <b>2018</b> , 200, 973-980	2.5	39
74	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , <b>2020</b> , 6, 479-489	5.1	39
73	Advances in intravesical drug delivery systems to treat bladder cancer. <i>International Journal of Pharmaceutics</i> , <b>2017</b> , 532, 105-117	6.5	37
72	The self-expanding metallic ureteric stent in the long-term management of benign ureteric strictures. <i>BJU International</i> , <b>2001</b> , 88, 339-42	5.6	36
71	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , <b>2020</b> , 78, 893-906	10.2	35
70	Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. <i>Bladder Cancer</i> , <b>2018</b> , 4, 395-401	1	35
69	A core outcome set for localised prostate cancer effectiveness trials. <i>BJU International</i> , <b>2017</b> , 120, E64-E70	3.9	34
68	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , <b>2019</b> , 5, 224-241	5.1	33
67	An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. <i>European Urology</i> , <b>2020</b> , 78, 546-569	10.2	30
66	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1697-1727	10.3	28
65	Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle. <i>Current Opinion in Urology</i> , <b>2018</b> , 28, 88-92	2.8	27
64	Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 496-507	8.7	25
63	Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). <i>BJU International</i> , <b>2012</b> , 109, 1579-82	5.6	22
62	Does urinary cytology have a role in haematuria investigations?. <i>BJU International</i> , <b>2019</b> , 123, 74-81	5.6	20
61	Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. <i>BJU International</i> , <b>2006</b> , 97, 509-12	5.6	18
60	The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-IBPHR study. <i>BJU International</i> , <b>1999</b> , 83, 243-8	5.6	17
59	Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , <b>2019</b> , 202, 1111-1119	2.5	17
58	BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). <i>European Urology</i> , <b>2019</b> , 75, 593-601	10.2	16

57	Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage. <i>Current Opinion in Urology</i> , <b>2020</b> , 30, 365-369	2.8	15
56	A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. <i>BJU International</i> , <b>1997</b> , 80, 116-22	5.6	15
55	The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. <i>BJU International</i> , <b>2001</b> , 88, 217-20	5.6	15
54	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 182-191	6.7	15
53	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 440-448	2.8	14
52	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , <b>2020</b> , 125, 817-826	5.6	12
51	Mesh erosion following laparoscopic incisional hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , <b>2012</b> , 16, 223-6	3.2	12
50	Measles, mumps and rubella -- the urologist's perspective. <i>International Journal of Clinical Practice</i> , <b>2006</b> , 60, 335-9	2.9	12
49	Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. <i>Journal of Internal Medicine</i> , <b>2019</b> , 285, 436-445	10.8	12
48	Exploring patients' experience and perception of being diagnosed with bladder cancer: a mixed-methods approach. <i>BJU International</i> , <b>2020</b> , 125, 669-678	5.6	11
47	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>European Urology Oncology</i> , <b>2021</b> , 4, 12-19	6.7	11
46	What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. <i>Current Opinion in Urology</i> , <b>2018</b> , 28, 570-576	2.8	11
45	Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. <i>Journal of Clinical Urology</i> , <b>2014</b> , 7, 90-98	0.2	10
44	Is it time to re-design the haematuria clinic?. <i>BJU International</i> , <b>2010</b> , 105, 585-8	5.6	10
43	Mixed-methods approach to exploring patients' perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. <i>BJU International</i> , <b>2019</b> , 124, 408-417	5.6	9
42	The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. <i>BJU International</i> , <b>2010</b> , 105 Suppl 2, 2-7	5.6	9
41	Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. <i>BJU International</i> , <b>2009</b> , 103, 726-9	5.6	9
40	Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. <i>BMJ Open</i> , <b>2019</b> , 9, e022268	3	8

39	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , <b>2019</b> , 123, 947-958	5.6	8
38	Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria. <i>World Journal of Urology</i> , <b>2021</b> , 39, 97-103	4	8
37	Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305). <i>BJU International</i> , <b>2009</b> , 104, 889-90	5.6	7
36	Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Bille, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>Eur Urol</i> 2017;71:447-61. <i>European Urology</i> , <b>2017</b> , 71, e173-e174	10.2	6
35	Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. <i>BMJ Open</i> , <b>2020</b> , 10, e041005	3	6
34	Do patients with frank haematuria referred under the two-week rule have a higher incidence of bladder cancer?. <i>Annals of the Royal College of Surgeons of England</i> , <b>2005</b> , 87, 345-7	1.4	6
33	Leydig cell tumour of the testis: a rare cause of male infertility. <i>BJU International</i> , <b>1998</b> , 81, 651	5.6	5
32	The Use of the NMP22 BladderChek Test for Bladder Cancer to Optimise Investigations in a One-Stop Haematuria Clinic. <i>British Journal of Medical and Surgical Urology</i> , <b>2008</b> , 1, 126-130		5
31	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16016-e16016	2.2	5
30	Does the nonurologic scientific community understand urothelial bladder cancer?. <i>European Urology</i> , <b>2014</b> , 66, 601-2	10.2	4
29	The management of hydronephrosis in patients undergoing TURBT. <i>International Urology and Nephrology</i> , <b>2006</b> , 38, 483-6	2.3	4
28	Rapid, Low-Cost Dielectrophoretic Diagnosis of Bladder Cancer in a Clinical Setting. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , <b>2020</b> , 8, 4300405	3	4
27	Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
26	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , <b>2018</b> , 4, 525-528	5.1	4
25	Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> ,	2.8	4
24	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. <i>BJU International</i> , <b>2021</b> , 128, 440-450	5.6	4
23	Interstitial Radiofrequency Therapy of the Prostate: Results of a Pilot Study. <i>Journal of Urology</i> , <b>1996</b> , 155, 1946-1949	2.5	3
22	En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3353-3358	4	3

21	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. <i>International Journal of Surgery Protocols</i> , <b>2020</b> , 21, 8-12	1.1	2
20	Diagnosis and treatment of non-muscle-invasive bladder cancer. <i>Trends in Urology &amp; Ments Health</i> , <b>2015</b> , 6, 23-27	0.3	2
19	Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guëin treatment for high-risk superficial bladder cancer. <i>International Urology and Nephrology</i> , <b>2007</b> , 39, 1039-41	2.3	2
18	RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. <i>Journal of Urology</i> , <b>2005</b> , 173, 1433-1433	2.5	2
17	A novel device for reconstituting and delivering intravesical chemotherapy. <i>BJU International</i> , <b>2003</b> , 92, 492	5.6	2
16	Emergency dorsal slit for balanitis with retention. <i>Journal of the Royal Society of Medicine</i> , <b>2004</b> , 97, 205-6	6.3	2
15	Radio-contrast enhancement of a urinary tract calculus. <i>Urologia Internationalis</i> , <b>1999</b> , 62, 127-9	1.9	2
14	What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?. <i>BJU International</i> , <b>2021</b> , 128, 225-235	5.6	2
13	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.. <i>European Urology</i> , <b>2022</b> ,	10.2	2
12	The Safe and Economical Care of Ta Bladder Cancer. <i>Urology Practice</i> , <b>2014</b> , 1, 176-183	0.8	1
11	The testicular tumour of adrenogenital syndrome: an unusual cause of male infertility. <i>BJU International</i> , <b>1998</b> , 81, 649-50	5.6	1
10	Intravesical BCG: where do we stand? Past, present and future. <i>Journal of Clinical Urology</i> , <b>2019</b> , 12, 425-435	4.35	1
9	Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , <b>2021</b> , 7, 307-315	1	1
8	Indications and Complications of Androgen Deprivation Therapy. <i>Seminars in Oncology Nursing</i> , <b>2020</b> , 36, 151042	3.7	0
7	Management of NMIBC during BCG shortage and COVID-19. <i>Trends in Urology &amp; Ments Health</i> , <b>2021</b> , 12, 7-11	0.3	0
6	TULA in recurrent non-muscle invasive bladder cancer. <i>Trends in Urology &amp; Ments Health</i> , <b>2020</b> , 11, 18-19	0.3	
5	Editorial comment to Maintenance intravesical bacillus Calmette-Guëin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. <i>International Journal of Urology</i> , <b>2010</b> , 17, 766-7	2.3	
4	Immediate Postoperative Instillation of Intravesical Mitomycin in Theatre: Outcome and Effect on Recurrence of Non Muscle-Invasive Bladder Cancer. <i>Current Urology</i> , <b>2009</b> , 3, 72-75	1.7	

- 3 Re: Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. *Journal of Urology*, **1998**, 159, 209-10 2.5
- 2 En Bloc Resection of Bladder Tumor-Is It the Way Forward?. *Frontiers in Surgery*, **2021**, 8, 685506 2.3
- 1 Early recurrence and the need for re-resection following Photodynamic diagnosis-assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group. *Journal of Clinical Urology*, **2021**, 14, 65-72 0.2